Opportunity Information: Apply for PA 09 253
Apply for PA 09 253
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Image guided Drug Delivery in Cancer (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Apr 10, 2013 and posted on Aug 12, 2009.
- Applicants must submit their applications by Apr 10, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses State governments Public and State controlled institutions of higher education City or township governments.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Image Guided Drug Delivery in Cancer (R01) opportunity (Funding Opportunity Number PA 09-253) is a National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement designed to push forward translational research that connects advanced medical imaging with how cancer drugs are delivered and how well they work in the body. The central emphasis is on building and validating quantitative, in vivo imaging approaches that can characterize image guided drug delivery (IGDD) in real time or near real time. In practical terms, the FOA is looking for projects that use imaging not just to "see" tumors, but to measure and verify key steps in drug delivery: identifying and characterizing the target, confirming that a therapeutic agent actually reaches and distributes within that target as intended, and tracking early and longer-term response to therapy after delivery.
A major theme of the announcement is the development of integrated, imaging-based platforms that support multifunctional and multiplexed drug delivery systems in cancer. This points to work that combines imaging with engineered delivery methods (for example, systems that can carry multiple payloads, perform multiple functions such as targeting plus therapy plus monitoring, or enable simultaneous measurement of several biological or pharmacologic parameters). The program focus is not limited to a single imaging modality; instead, it encourages innovative combinations and quantitative strategies that can reliably validate delivery, characterize target engagement, and provide objective readouts of treatment response, all in living systems.
From a translational standpoint, the FOA explicitly welcomes studies that move beyond small-animal proof-of-concept and toward clinical readiness. That includes validation studies in non-human primates or other large animal models where appropriate, as well as first-in-human studies aimed at translating IGDD technologies into clinical oncology. The key idea is to support work that can credibly bridge the gap between laboratory innovation and real clinical implementation, including the kinds of validation steps needed to demonstrate that an imaging-guided delivery approach is measurable, reproducible, and relevant to patient care.
The award mechanism is the NIH Research Project Grant (R01), meaning applicants are expected to propose a well-developed, hypothesis-driven or milestone-driven research plan with sufficient preliminary rationale and a clear path to meaningful outcomes in the IGDD space. Funding availability and the number of awards are not fixed; awards depend on the availability of funds and on receiving a sufficient number of highly meritorious applications, which is typical for NIH discretionary grant programs.
Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses and other for-profit entities), and a range of government entities (state, county, city/township, and special district governments). The announcement also notes eligibility for certain additional categories such as eligible federal agencies, Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, U.S. territories or possessions, regional organizations, and foreign organizations. There is no cost sharing or matching requirement.
For reference details, the opportunity was posted on Aug 12, 2009, with an original closing date of Sep 7, 2012, and a later listed closing date of Apr 10, 2013, followed by an archive date of May 10, 2013. It is associated with CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research). The full announcement was available through the NIH Grants Guide (link provided in the source), and administrative help for access or linking issues was routed through the NIH Office of Extramural Research webmaster contact listed in the notice.
Frequently Asked Questions (FAQs): Image Guided Drug Delivery in Cancer (R01) - PA 09-253
What is the purpose of the Image Guided Drug Delivery in Cancer (R01) funding opportunity (PA 09-253)?
This National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement supports translational research that links advanced medical imaging with how cancer drugs are delivered and how well they work in the body. The core goal is to develop and validate quantitative, in vivo imaging approaches that can characterize image guided drug delivery (IGDD) in real time or near real time.
What does "image guided drug delivery (IGDD)" mean in the context of this FOA?
In this opportunity, IGDD refers to using imaging not only to visualize tumors, but to quantitatively measure and verify key steps of drug delivery in living systems. This includes identifying and characterizing the target, confirming that a therapeutic agent reaches and distributes within that target, and tracking early and longer-term response to therapy after delivery.
What kinds of research activities are emphasized?
The FOA emphasizes building and validating quantitative in vivo imaging methods and integrated imaging-based platforms that can objectively assess drug delivery and response. A central focus is on measurable, reproducible approaches that can verify delivery, characterize target engagement, and provide objective readouts of treatment response.
Is this opportunity focused on a specific imaging modality?
No. The program focus is not limited to a single imaging modality. It encourages innovative combinations of imaging methods and quantitative strategies that can reliably validate delivery and characterize treatment response in living systems.
How is imaging expected to be used beyond simply "seeing" a tumor?
The FOA is looking for imaging approaches that can quantify and validate the delivery process, such as confirming that a therapeutic agent reaches the intended target, determining how it distributes within that target, and monitoring early and longer-term response after delivery.
What does the FOA mean by "quantitative, in vivo imaging approaches"?
It refers to imaging methods used in living systems that generate measurable, objective data (not just qualitative images) about drug delivery and therapeutic response, ideally in real time or near real time.
What is meant by "integrated, imaging-based platforms" in this announcement?
These are combined systems that use imaging as a core component of the drug delivery and evaluation workflow. The intent is to support platforms that can validate delivery, measure target engagement, and assess response in a unified, imaging-driven framework.
What are "multifunctional and multiplexed drug delivery systems" as described here?
The FOA highlights drug delivery systems that may carry multiple payloads, perform multiple functions (for example targeting plus therapy plus monitoring), or enable simultaneous measurement of several biological or pharmacologic parameters, with imaging supporting and validating these capabilities.
Does the FOA support translational research and clinical readiness work?
Yes. The FOA explicitly welcomes studies that move beyond small-animal proof-of-concept toward clinical readiness. It includes validation in non-human primates or other large animal models where appropriate, and also welcomes first-in-human studies aimed at translating IGDD technologies into clinical oncology.
Are small-animal proof-of-concept studies excluded?
The FOA encourages moving beyond small-animal proof-of-concept and toward clinical readiness, but the emphasis in the description provided is on translation and the validation steps needed for credible clinical implementation.
What is the intended endpoint or impact of projects funded under this FOA?
The intended impact is to bridge laboratory innovation and real clinical implementation by supporting work that demonstrates imaging-guided delivery approaches are measurable, reproducible, and relevant to patient care, including validation of delivery and objective assessment of treatment response.
What is the award mechanism for this opportunity?
The award mechanism is the NIH Research Project Grant (R01). Applicants are expected to propose a well-developed, hypothesis-driven or milestone-driven research plan with adequate preliminary rationale and a clear path to meaningful outcomes in IGDD.
Is the number of awards or total funding amount fixed?
No. Funding availability and the number of awards are not fixed. Awards depend on the availability of funds and on receiving a sufficient number of highly meritorious applications.
Who is sponsoring this opportunity?
The opportunity is a National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement.
Who is eligible to apply?
Eligibility is broad and includes many domestic and non-domestic organizations. Eligible applicants include public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses), and government entities such as state, county, city/township, and special district governments.
Are foreign organizations eligible?
Yes. The announcement notes that foreign organizations are eligible.
Are specific institution types like HBCUs and Hispanic-serving Institutions eligible?
Yes. The eligibility categories explicitly include Historically Black Colleges and Universities (HBCUs) and Hispanic-serving Institutions.
Are U.S. territories or possessions eligible to apply?
Yes. The eligibility information includes U.S. territories or possessions.
Are federal agencies eligible to apply?
The eligibility section notes that certain additional categories are eligible, including eligible federal agencies.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement for this opportunity.
What are the key dates listed for this opportunity?
The opportunity was posted on Aug 12, 2009. It lists an original closing date of Sep 7, 2012, and a later listed closing date of Apr 10, 2013. The archive date is May 10, 2013.
What CFDA numbers are associated with this FOA?
The opportunity is associated with CFDA 93.394 (Cancer Detection and Diagnosis Research) and CFDA 93.395 (Cancer Treatment Research).
Where was the full announcement made available?
The full announcement was available through the NIH Grants Guide (via the link referenced in the source information).
Who should be contacted for help with access or linking issues related to the announcement?
Administrative help for access or linking issues was routed through the NIH Office of Extramural Research webmaster contact listed in the notice.
Browse more opportunities from the same category: Education Health
Next opportunity: Elections, Political Participation, and Consensus Building in AF, NEA, and SA
Previous opportunity: Optimization of Small Molecule Probes for the Nervous System (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 253
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 253) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Biology of Estrogen Receptor Negative Breast Cancer in Various Racial and Ethnic Groups (U01) Apply for RFA CA 09 026 Funding Number: RFA CA 09 026 Agency: National Institutes of Health Category: Education Health Funding Amount: $667,000 |
| Nutrition and Physical Activity Research to Promote Cardiovascular and Pulmonary Health (R01) Apply for PA 09 243 Funding Number: PA 09 243 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Nutrition and Physical Activity Research to Promote Cardiovascular and Pulmonary Health (R21) Apply for PA 09 244 Funding Number: PA 09 244 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Optimization of Small Molecule Probes for the Nervous System (STTR R41) Apply for PAR 09 259 Funding Number: PAR 09 259 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Optimization of Small Molecule Probes for the Nervous System (SBIR R43) Apply for PAR 09 260 Funding Number: PAR 09 260 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 09 019 Funding Number: RFA RM 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition for Research Centers in Minority Institutions Infrastructure for Clinical and Translational Research (RCTR) U54 Apply for PAR 09 261 Funding Number: PAR 09 261 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R01) Apply for RFA DA 10 010 Funding Number: RFA DA 10 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R21) Apply for RFA DA 10 011 Funding Number: RFA DA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Targeted Library Synthesis and Screening at Novel Targets for Potential Drug Addiction Treatments and Research Tools (R21/R33) Apply for RFA DA 10 005 Funding Number: RFA DA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) Apply for RFA GM 10 009 Funding Number: RFA GM 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Developing Research Capacity in Africa for Studies on HIV Associated Malignancies (D43) Apply for RFA CA 09 016 Funding Number: RFA CA 09 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Medications Development for Cannabis Related Disorders (R01) Apply for RFA DA 10 016 Funding Number: RFA DA 10 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50) Apply for PAR 10 003 Funding Number: PAR 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 10 002 Funding Number: PAR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 10 001 Funding Number: PAR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training (U54) Apply for RFA CA 09 032 Funding Number: RFA CA 09 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $900,000 |
| Pathway to Independence Award in Cancer Nanotechnology Research (K99/R00) Apply for RFA CA 09 015 Funding Number: RFA CA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Nanotechnology Training Centers (CNTCs)(R25) Apply for RFA CA 09 014 Funding Number: RFA CA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 10 012 Funding Number: PA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 253", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.